贝瑞基因(000710) - 2019 Q1 - 季度财报

Financial Performance - The company's revenue for Q1 2019 was ¥332,884,487.18, representing a 12.01% increase compared to ¥297,185,149.31 in the same period last year[7]. - Net profit attributable to shareholders was ¥167,685,430.87, a significant increase of 155.36% from ¥65,667,179.26 year-on-year[7]. - The basic earnings per share rose to ¥0.4729, up 155.35% from ¥0.1852 in the previous year[7]. - Net profit for Q1 2019 reached CNY 166,625,153.50, a significant increase of 152.3% from CNY 65,969,830.36 in Q1 2018[44]. - The company expects a net profit attributable to shareholders of approximately CNY 235 million for the first half of 2019, representing a significant increase of 61.10% compared to the same period last year[24]. - Basic earnings per share are projected to grow to CNY 0.6627, reflecting an increase of 61.10% year-on-year[24]. Assets and Liabilities - The total assets at the end of the reporting period were ¥2,516,911,140.42, reflecting a 15.56% increase from ¥2,177,996,626.15 at the end of the previous year[7]. - The company’s total assets reached CNY 2,516,911,140.42 as of March 31, 2019, up from CNY 2,177,996,626.15 at the end of 2018[34]. - The company’s total liabilities increased to CNY 392,483,348.34 from CNY 235,675,610.33, indicating a rise in financial obligations[35]. - The total liabilities of the company stood at 235,675,610.33 CNY, with total assets amounting to 2,177,996,626.15 CNY, resulting in a debt-to-asset ratio of approximately 10.8%[60]. - Total current assets amounted to ¥185,380,375.57 as of December 31, 2018[62]. - Total non-current assets were ¥4,548,358,596.62, leading to total assets of ¥4,733,738,972.19[62]. Cash Flow - The net cash flow from operating activities was negative at -¥16,708,011.17, a decline of 141.61% compared to ¥40,157,828.41 in the same period last year[7]. - Cash received from tax refunds increased by 1656.05% to ¥1,896,862.91 due to a rise in tax refunds received[16]. - The net cash flow from operating activities was -26,772,013.33 CNY, compared to -3,520,963.28 CNY in the previous period, indicating a significant decline in operational cash generation[54]. - The company reported a significant investment income of CNY 85,411,865.40 in Q1 2019, compared to a loss of CNY 373,081.83 in the same period last year[44]. - The cash outflow from investment activities totaled 206,133,603.73 CNY, compared to 35,211,235.04 CNY in the previous period, showing a substantial increase in investment expenditures[53]. Shareholder Information - The number of shareholders at the end of the reporting period was 14,747[11]. - The top shareholder, Tianjin Junruiqi Equity Investment Partnership, held 14.55% of the shares, amounting to 51,605,030 shares[11]. - The company did not engage in any repurchase transactions during the reporting period[12]. Investments and Expenditures - Long-term equity investments grew by 167.37% to ¥207,631,750.70 as a result of new investments in joint ventures[15]. - Cash paid for fixed assets and other long-term assets rose by 462.77% to ¥164,390,843.24 due to increased investment in gene testing equipment[16]. - The company invested 13,000,000.00 CNY in fixed assets and other long-term assets, an increase from 10,000,224.00 CNY in the previous period, representing a 30% rise in investment activities[56]. Operational Challenges - Management expenses decreased by 32.61% to ¥23,416,960.60 as R&D costs were separately listed[16]. - The company reported a significant increase in management expenses compared to the previous period, indicating potential operational challenges[47]. - The company experienced a foreign exchange loss of 969,780.15 CNY during the period, which impacted the overall cash position[53]. Accounting and Reporting - The company adjusted its financial reporting to comply with new accounting standards effective January 1, 2019, impacting the classification of financial assets[64]. - The company did not perform retrospective adjustments for prior period comparative data under the new financial instrument standards[65]. - The first quarter report for 2019 was not audited[65].